Mounjaro, Zepbound shortage eases
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded versions of the medications.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly's weight-loss drug removed from FDA's shortage list
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
GlobalData on MSN16h
NHS proposes phased launch for Eli Lilly’s Mounjaro
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
BioSpace18h
Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing
Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...
National Health Executive20h
Mounjaro: NICE consults on NHSE proposals for ’unprecedented’ obesity drug roll-out
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
She took Ozempic, now she can't eat without vomiting. Lawsuit claims the drug made her ill
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
England’s NHS to Offer Eli Lilly Obesity Drug to Some Patients
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...
Millions may miss out on 'King Kong' weight loss drug, experts warn
In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...